Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

▤ Summary

Athira Pharma signed an exclusive global license for lasofoxifene from Sermonix Pharmaceuticals to develop and commercialize the Phase 3 metastatic breast cancer program. The company also announced a private placement that can raise up to $236 million, with the proceeds supporting lasofoxifene development and its broader pipeline. The Phase 3 ELAINE-3 trial is already more than 50% enrolled, and Athira expects topline data in mid-2027. The deal includes milestone payments, royalties, and a conference call to discuss the transaction and financing. This move gives Athira fresh capital and control over a late-stage oncology asset with potential regulatory significance.

$ Funding

▦ Linked Companies